CoChat

Translational control and the cancer cell response to stress

Open access
Robichaud, Nathaniel, Sonenberg, Nahum · 2017 · Current Opinion in Cell Biology
Cited by 70

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

The evidence for the importance of aberrant translation in cancer cells is overwhelming. Reflecting the wealth of data, there are excellent reviews delineating how ribosomes and initiation factors are linked to cancer [1-3], and the therapeutic strategies being devised to target them [4]. Changes in translational efficiency can engender a malignant phenotype without the need for chromatin reorganization, transcription, splicing and mRNA export [5,6]. Thus, cancer-related modulations of the translational machinery are ideally suited to allow cancer cells to respond to the various stresses encountered along the path of tumorigenesis and organism-wide dissemination [7•,8,9,10•]. Emerging findings supporting this notion are the focus of this review.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ceb.2017.05.007

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 75

  1. Gentilella, 2015, A liaison between mTOR signaling, ribosome biogenesis and cancer, Biochim. Biophys. Acta, 1849, 812, 10.1016/j.bbagrm.2015.02.005 · DOI
  2. Ruggero, 2013, Translational control in cancer etiology, Cold Spring Harb. Perspect. Biol., 5, 10.1101/cshperspect.a012336 · DOI · Paper page
  3. Spriggs, 2010, Translational regulation of gene expression during conditions of cell stress, Mol. Cell, 40, 228, 10.1016/j.molcel.2010.09.028 · DOI · Paper page
  4. de Nadal, 2011, Controlling gene expression in response to stress, Nat. Rev. Genet., 12, 833, 10.1038/nrg3055 · DOI · Paper page
  5. Truitt, 2015, Differential requirements for eIF4E dose in normal development and cancer, Cell, 162, 59, 10.1016/j.cell.2015.05.049 · DOI · Paper page
  6. Martinez, 2015, Phosphorylation of eIF4E confers resistance to cellular stress and DNA-damaging agents through an interaction with 4E-T: a rationale for novel therapeutic approaches, PLoS One, 10, e0123352, 10.1371/journal.pone.0123352 · DOI
  7. Chen, 2010, Differential regulation of CHOP translation by phosphorylated eIF4E under stress conditions, Nucleic Acids Res., 38, 764, 10.1093/nar/gkp1034 · DOI
  8. Avdulov, 2015, eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cells, Cancer Res., 75, 687, 10.1158/0008-5472.CAN-14-2571 · DOI
  9. Buttgereit, 1995, A hierarchy of ATP-consuming processes in mammalian cells, Biochem. J., 312, 163, 10.1042/bj3120163 · DOI · Paper page
  10. Tahmasebi, 2016, Control of embryonic stem cell self-renewal and differentiation via coordinated alternative splicing and translation of YY2, Proc. Natl. Acad. Sci. U. S. A., 10.1073/pnas.1615540113 · DOI
  11. Lazaris-Karatzas, 1990, Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap, Nature, 345, 544, 10.1038/345544a0 · DOI · Paper page
  12. De Benedetti, 1999, eIF4E expression in tumors: its possible role in progression of malignancies, Int. J. Biochem. Cell Biol., 31, 59, 10.1016/S1357-2725(98)00132-0 · DOI · Paper page
  13. Oblinger, 2016, Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas, Neuro Oncol., 18, 1265, 10.1093/neuonc/now032 · DOI
  14. Martinez-Saez, 2016, peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas, Cancer Med., 5, 2501, 10.1002/cam4.817 · DOI
  15. Jiang, 2016, Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma, J. Cancer Res. Clin. Oncol., 142, 2309, 10.1007/s00432-016-2232-2 · doi:10.1007/s00432-016-2232-2
  16. Carter, 2016, Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma, Br. J. Cancer, 114, 444, 10.1038/bjc.2015.450 · DOI
  17. Gandin, 2016, nanoCAGE reveals 5′ UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs, Genome Res., 26, 636, 10.1101/gr.197566.115 · DOI · Paper page
  18. Koromilas, 2015, Roles of the translation initiation factor eIF2alpha serine 51 phosphorylation in cancer formation and treatment, Biochim. Biophys. Acta, 1849, 871, 10.1016/j.bbagrm.2014.12.007 · DOI
  19. Wang, 1999, Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin’s lymphomas, Am. J. Pathol., 155, 247, 10.1016/S0002-9440(10)65118-8 · doi:10.1016/s0002-9440(10)65118-8
  20. Rosenwald, 2001, Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung, Cancer, 92, 2164, 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A · doi:10.1002/1097-0142(20011015)92:8<2164::aid-cncr1559>3.0.co;2-a
  21. Kim, 2002, Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR, Oncogene, 21, 8741, 10.1038/sj.onc.1205987 · DOI
  22. Ye, 2010, The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation, EMBO J., 29, 2082, 10.1038/emboj.2010.81 · DOI · Paper page
  23. Kozel, 2016, Overexpression of eIF5 or its protein mimic 5MP perturbs eIF2 function and induces ATF4 translation through delayed re-initiation, Nucleic Acids Res., 44, 8704, 10.1093/nar/gkw559 · DOI
  24. Gandin, 2016, mTORC1 and CK2 coordinate ternary and eIF4F complex assembly, Nat. Commun., 7, 11127, 10.1038/ncomms11127 · DOI · Paper page
  25. Rajesh, 2015, Phosphorylation of the translation initiation factor eIF2alpha at serine 51 determines the cell fate decisions of Akt in response to oxidative stress, Cell Death Dis., 6, e1591, 10.1038/cddis.2014.554 · DOI
  26. Dennis, 2013, Regulated in DNA damage and development 1 (REDD1) promotes cell survival during serum deprivation by sustaining repression of signaling through the mechanistic target of rapamycin in complex 1 (mTORC1), Cell Signal., 25, 2709, 10.1016/j.cellsig.2013.08.038 · DOI
  27. Whitney, 2009, ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression, Biochem. Biophys. Res. Commun., 379, 451, 10.1016/j.bbrc.2008.12.079 · DOI · Paper page
  28. Ruggero, 2004, The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis, Nat. Med., 10, 484, 10.1038/nm1042 · DOI · Paper page
  29. Petroulakis, 2009, p53-dependent translational control of senescence and transformation via 4E-BPs, Cancer Cell, 16, 439, 10.1016/j.ccr.2009.09.025 · DOI
  30. Larsson, 2007, Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors, Cancer Res., 67, 6814, 10.1158/0008-5472.CAN-07-0752 · DOI · Paper page
  31. Musa, 2016, Dual mTORC1/2 inhibition as a novel strategy for the resensitization and treatment of platinum-resistant ovarian cancer, Mol. Cancer Ther., 15, 1557, 10.1158/1535-7163.MCT-15-0926 · DOI
  32. Larsson, 2006, Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure, Nucleic Acids Res., 34, 4375, 10.1093/nar/gkl558 · DOI · Paper page
  33. Lazaris-Karatzas, 1992, The mRNA 5′ cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts, Mol. Cell Biol., 12, 1234
  34. Rinker-Schaeffer, 1993, Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts, Int. J. Cancer, 55, 841, 10.1002/ijc.2910550525 · DOI · Paper page
  35. Rajesh, 2013, eIF2alpha phosphorylation bypasses premature senescence caused by oxidative stress and pro-oxidant antitumor therapies, Aging (Albany NY), 5, 884, 10.18632/aging.100620 · DOI
  36. Horiguchi, 2012, Stress-regulated transcription factor ATF4 promotes neoplastic transformation by suppressing expression of the INK4a/ARF cell senescence factors, Cancer Res., 72, 395, 10.1158/0008-5472.CAN-11-1891 · DOI · Paper page
  37. Bengsch, 2015, Comprehensive analysis of the ubiquitinome during oncogene-induced senescence in human fibroblasts, Cell Cycle, 14, 1540, 10.1080/15384101.2015.1026492 · DOI
  38. Koritzinsky, 2006, Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control, EMBO J., 25, 1114, 10.1038/sj.emboj.7600998 · DOI · Paper page
  39. Bennewith, 2004, Quantifying transient hypoxia in human tumor xenografts by flow cytometry, Cancer Res., 64, 6183, 10.1158/0008-5472.CAN-04-0289 · DOI · Paper page
  40. Lehman, 2015, Translational upregulation of an individual p21Cip1 transcript variant by GCN2 regulates cell proliferation and survival under nutrient stress, PLoS Genet., 11, e1005212, 10.1371/journal.pgen.1005212 · DOI · Paper page
  41. Leprivier, 2015, Stress-mediated translational control in cancer cells, Biochim. Biophys. Acta, 1849, 845, 10.1016/j.bbagrm.2014.11.002 · DOI
  42. Braunstein, 2007, A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer, Mol. Cell, 28, 501, 10.1016/j.molcel.2007.10.019 · DOI · Paper page
  43. Joshi, 2004, Characterization of mammalian eIF4E-family members, Eur. J. Biochem., 271, 2189, 10.1111/j.1432-1033.2004.04149.x · DOI · Paper page
  44. Zuberek, 2007, Weak binding affinity of human 4EHP for mRNA cap analogs, RNA, 13, 691, 10.1261/rna.453107 · DOI
  45. Lee, 2016, eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation, Nature, 536, 96, 10.1038/nature18954 · DOI · Paper page
  46. Connolly, 2006, Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells, Mol. Cell Biol., 26, 3955, 10.1128/MCB.26.10.3955-3965.2006 · DOI · Paper page
  47. Yi, 2013, Hypoxia-inducible factor-1alpha (HIF-1alpha) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions, J. Biol. Chem., 288, 18732, 10.1074/jbc.M113.471466 · DOI · Paper page
  48. Nathan, 1997, Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas, Oncogene, 15, 1087, 10.1038/sj.onc.1201272 · DOI
  49. Scott, 1998, Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E, Br. J. Cancer, 77, 2120, 10.1038/bjc.1998.356 · DOI
  50. Dodd, 2015, mTORC1 drives HIF-1alpha and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3, Oncogene, 34, 2239, 10.1038/onc.2014.164 · DOI · Paper page
  51. Frydryskova, 2016, Distinct recruitment of human eIF4E isoforms to processing bodies and stress granules, BMC Mol. Biol., 17, 21, 10.1186/s12867-016-0072-x · DOI
  52. Zucal, 2015, EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition, BMC Cancer, 15, 855, 10.1186/s12885-015-1845-1 · DOI
  53. Larsson, 2012, Distinct perturbation of the translatome by the antidiabetic drug metformin, Proc. Natl. Acad. Sci. U. S. A., 109, 8977, 10.1073/pnas.1201689109 · DOI · Paper page
  54. Tamarkin-Ben-Harush, 2017, Cap-proximal nucleotides via differential eIF4E binding and alternative promoter usage mediate translational response to energy stress, Elife, 6, 10.7554/eLife.21907 · DOI · Paper page
  55. Dong, 2009, Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells, Breast Cancer Res. Treat., 113, 443, 10.1007/s10549-008-9956-x · DOI
  56. Zhou, 2011, Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells, Med. Oncol., 28, 1302, 10.1007/s12032-010-9630-0 · DOI
  57. Boussemart, 2014, eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies, Nature, 10.1038/nature13572 · DOI · Paper page
  58. Yu, 2016, eIF4E-phosphorylation-mediated Sox2 upregulation promotes pancreatic tumor cell repopulation after irradiation, Cancer Lett., 375, 31, 10.1016/j.canlet.2016.02.052 · DOI
  59. Grzmil, 2016, Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy, Cell Signal., 28, 1412, 10.1016/j.cellsig.2016.06.005 · DOI
  60. Jeon, 2016, Salubrinal-mediated upregulation of eIF2alpha phosphorylation increases doxorubicin sensitivity in MCF-7/ADR cells, Mol. Cells, 39, 129, 10.14348/molcells.2016.2243 · DOI
  61. Schewe, 2009, Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy, Cancer Res., 69, 1545, 10.1158/0008-5472.CAN-08-3858 · DOI
  62. Pola, 2013, Vitronectin-alphavbeta3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells, Cancer Res., 73, 4571, 10.1158/0008-5472.CAN-13-0218 · DOI
  63. Gorrini, 2005, Fibronectin controls cap-dependent translation through beta1 integrin and eukaryotic initiation factors 4 and 2 coordinated pathways, Proc. Natl. Acad. Sci. U. S. A., 102, 9200, 10.1073/pnas.0409513102 · DOI
  64. Nasr, 2013, eIF4F suppression in breast cancer affects maintenance and progression, Oncogene, 32, 861, 10.1038/onc.2012.105 · DOI · Paper page
  65. Robichaud, 2015, Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3, Oncogene, 34, 2032, 10.1038/onc.2014.146 · DOI · Paper page
  66. Ghosh, 2009, Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation, ACS Chem. Biol., 4, 367, 10.1021/cb9000475 · DOI · Paper page
  67. Pettersson, 2015, Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis, Cancer Res., 75, 1102, 10.1158/0008-5472.CAN-14-1996 · DOI
  68. Grzmil, 2011, MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma, Cancer Res., 71, 2392, 10.1158/0008-5472.CAN-10-3112 · DOI
  69. Graff, 2009, eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival, Cancer Res., 69, 3866, 10.1158/0008-5472.CAN-08-3472 · DOI · Paper page
  70. Lee, 2015, Prognostic significance of phosphorylated 4E-binding protein 1 in non-small cell lung cancer, Int. J. Clin. Exp. Pathol., 8, 3955
  71. Heikkinen, 2013, Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment, Breast Cancer Res. Treat., 141, 79, 10.1007/s10549-013-2671-2 · DOI
  72. Campbell, 2015, Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma, Am. J. Cancer Res., 5, 2838
  73. Mujcic, 2013, Hypoxic activation of the PERK/eIF2alpha arm of the unfolded protein response promotes metastasis through induction of LAMP3, Clin. Cancer Res., 19, 6126, 10.1158/1078-0432.CCR-13-0526 · DOI · Paper page
  74. Hong, 2011, A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer, Clin. Cancer Res., 17, 6582, 10.1158/1078-0432.CCR-11-0430 · DOI · Paper page
  75. Duffy, 2016, Modulation of tumor eIF4E by antisense inhibition: a phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer, Int. J. Cancer, 139, 1648, 10.1002/ijc.30199 · DOI

Cited by

See all 70

Metadata

Authors
Robichaud, N., & Sonenberg, N.
Venue
Current Opinion in Cell Biology
Publisher
Elsevier BV
Published
2017-04
Volume
45
Pages
102-109
ISSN
0955-0674 (ISSN-L)
OpenAlex
W2621232571
Cited by
70
References
20
FWCI
0.88
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.